Supplement
MitoQ (Mitoquinone)
SaveA mitochondria-targeted form of CoQ10 conjugated to a triphenylphosphonium cation. It accumulates in mitochondria at concentrations hundreds of times higher than untargeted CoQ10.
Quick verdict
Innovative delivery mechanism with strong preclinical data and emerging human evidence for vascular and mitochondrial health. More expensive than standard CoQ10.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
MitoQ concentrates in mitochondria 100-1000x more than dietary CoQ10 due to its lipophilic cation. Human trials show improved vascular endothelial function in older adults (reversed ~15-20 years of aging in one measure). Being studied for Parkinson's disease, liver disease, and metabolic syndrome. A Phase II PD trial was negative.
Benefits
- Mitochondria-targeted delivery far exceeding standard CoQ10
- Improved vascular endothelial function in older adults
- Reduces mitochondrial oxidative stress
Dosage notes
Standard dose: 10-20 mg daily, taken in the morning on an empty stomach.
Side effects
- Generally well-tolerated
- Mild GI discomfort
- Headache
Who should be cautious
Limited long-term human safety data. Phase II Parkinson's trial showed no efficacy despite mechanistic rationale. Expensive.
What this page cannot tell you
Clinical trial data is still limited. The failed Parkinson's trial tempers enthusiasm despite positive vascular data. Long-term effects of sustained mitochondrial antioxidant supplementation are unknown.
Leaderboard scores
- Longevity45
- Energy35
Write a review
Sign in to write a review.